BioCentury | Aug 4, 2018
Finance

Functions of formulation

...returned rights to one target to Halozyme in 2017; (B) The deal was terminated after ViroPharma Inc....
...12/21/12 Intrexon Corp. (NYSE:XON) 1 Endocrine/Metabolic Recombinant human α 1-antitrypsin $9 $54 $63 11% 06/06/11 ViroPharma Inc....
...$305 $6,349 $6,654 Only one of the biotech’s Enhanze deals has been terminated, after partner ViroPharma Inc....
BioCentury | Jan 27, 2018
Finance

All together now

...of ViroPharma Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired in 2014 for $4.2 billion to obtain ViroPharma’s...
BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

...complimentary segments of the market. The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc....
...Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Neurology Elizabeth S. Eaton Adderall XR Advate Adynovate Elvanse Obizur Recombinate Baxalta Inc. Dyax Corp. Jerini AG Shire plc ViroPharma Inc. Adrenergic...
BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

...complimentary segments of the market. The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc....
...in London and gained $1.69 to $150.79 in New York. Elizabeth S. Eaton Adderall XR Elvanse Dyax Corp. Jerini AG Shire plc ViroPharma Inc....
BioCentury | Feb 9, 2017
Company News

Vancocin vancomycin news

...In a federal lawsuit, the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of...
...violated antitrust laws to delay generic competition for antibiotic Vancocin vancomycin. The FTC alleged that ViroPharma...
...suit in the U.S. District Court for the District of Delaware. According to the complaint, ViroPharma...
BioCentury | Feb 8, 2017
Company News

FTC suit alleges Shire abused FDA process

...In a federal lawsuit , the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary...
...violated antitrust laws to delay generic competition for antibiotic Vancocin vancomycin. The FTC alleged that ViroPharma...
...suit in the U.S. District Court for the District of Delaware. According to the complaint, ViroPharma...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

...and is typically used by those who have less severe disease. The 2014 acquisition of ViroPharma Inc....
...as it is about gaining the asset," he told BioCentury last week. Ornskov offered the ViroPharma...
...a world-leading team managing that," Ornskov said. John Carlisle was VP of plasma operations at ViroPharma...
BioCentury | Jan 4, 2016
Product Development

Turnabout

...CMV after showing efficacy in Phase II when the endpoint was assessed earlier. In 2009, ViroPharma Inc....
...at week 24 post-transplant. In Phase II, maribavir met the primary endpoint at week 12. ViroPharma...
BioCentury | Dec 19, 2015
Company News

Soland replaces Aldag as uniQure CEO

...down as soon as a replacement could be found. Soland was VP and COO at ViroPharma Inc....
BioCentury | Nov 9, 2015
Finance

HAE maker

...acute HAE attacks. In 2013, Shire added a prophylactic - Cinryze - when it bought ViroPharma Inc....
Items per page:
1 - 10 of 643
BioCentury | Aug 4, 2018
Finance

Functions of formulation

...returned rights to one target to Halozyme in 2017; (B) The deal was terminated after ViroPharma Inc....
...12/21/12 Intrexon Corp. (NYSE:XON) 1 Endocrine/Metabolic Recombinant human α 1-antitrypsin $9 $54 $63 11% 06/06/11 ViroPharma Inc....
...$305 $6,349 $6,654 Only one of the biotech’s Enhanze deals has been terminated, after partner ViroPharma Inc....
BioCentury | Jan 27, 2018
Finance

All together now

...of ViroPharma Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired in 2014 for $4.2 billion to obtain ViroPharma’s...
BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

...complimentary segments of the market. The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc....
...Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Neurology Elizabeth S. Eaton Adderall XR Advate Adynovate Elvanse Obizur Recombinate Baxalta Inc. Dyax Corp. Jerini AG Shire plc ViroPharma Inc. Adrenergic...
BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

...complimentary segments of the market. The pharma used three acquisitions -- Jerini AG in 2008, ViroPharma Inc....
...in London and gained $1.69 to $150.79 in New York. Elizabeth S. Eaton Adderall XR Elvanse Dyax Corp. Jerini AG Shire plc ViroPharma Inc....
BioCentury | Feb 9, 2017
Company News

Vancocin vancomycin news

...In a federal lawsuit, the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary of...
...violated antitrust laws to delay generic competition for antibiotic Vancocin vancomycin. The FTC alleged that ViroPharma...
...suit in the U.S. District Court for the District of Delaware. According to the complaint, ViroPharma...
BioCentury | Feb 8, 2017
Company News

FTC suit alleges Shire abused FDA process

...In a federal lawsuit , the U.S. Federal Trade Commission alleged that the Shire ViroPharma Inc. subsidiary...
...violated antitrust laws to delay generic competition for antibiotic Vancocin vancomycin. The FTC alleged that ViroPharma...
...suit in the U.S. District Court for the District of Delaware. According to the complaint, ViroPharma...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

...and is typically used by those who have less severe disease. The 2014 acquisition of ViroPharma Inc....
...as it is about gaining the asset," he told BioCentury last week. Ornskov offered the ViroPharma...
...a world-leading team managing that," Ornskov said. John Carlisle was VP of plasma operations at ViroPharma...
BioCentury | Jan 4, 2016
Product Development

Turnabout

...CMV after showing efficacy in Phase II when the endpoint was assessed earlier. In 2009, ViroPharma Inc....
...at week 24 post-transplant. In Phase II, maribavir met the primary endpoint at week 12. ViroPharma...
BioCentury | Dec 19, 2015
Company News

Soland replaces Aldag as uniQure CEO

...down as soon as a replacement could be found. Soland was VP and COO at ViroPharma Inc....
BioCentury | Nov 9, 2015
Finance

HAE maker

...acute HAE attacks. In 2013, Shire added a prophylactic - Cinryze - when it bought ViroPharma Inc....
Items per page:
1 - 10 of 643